Search | Clinical Trials Finder

Conditions: Migraine Disorders
Interventions: ALD403 (Eptinezumab), Placebo; Biological
Lead sponsor: Alder Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more

Conditions: Tourette Syndrome
Interventions: SCI-110, Placebo; Drug · Other
Lead sponsor: Neurothera Labs Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anorexia Nervosa
Interventions: quetiapine; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 58
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 29
States / cities: Buena Park, California • Chino, California • Long Beach, California + 19 more

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions: NBI-921352, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Ileus
Interventions: Alvimopam, 300 mg Polyethylene; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: American Fork, Utah • Cedar City, Utah • Logan, Utah + 6 more

Conditions: Asthma
Interventions: Fluticasone Propionate (FP); Drug
Lead sponsor: Dey; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rock Hill, South Carolina

Conditions: Major Depressive Disorder (MDD)
Interventions: DT-101, Placebo; Drug
Lead sponsor: Draig Therapeutics Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more

Conditions: Acute Otitis Media
Interventions: AR01, Glycerin ear drops; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 29
States / cities: Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more

Conditions: Excessive Daytime Sleepiness
Interventions: ORX142 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Lincoln, Nebraska • Eatontown, New Jersey • New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Healthy
Interventions: Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid; Drug · Dietary Supplement
Lead sponsor: Carsten Skarke, MD; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance-Related Disorders
Interventions: Rivastigmine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions: BIBW 2948 BS; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more

Conditions: Cardiovascular Disease
Interventions: Rimonabant, Placebo (for Rimonabant); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 18,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: COPD
Interventions: Advair 250, Placebo- matched, Placebo, Advair 250 - matched; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Colitis, Ulcerative
Interventions: Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: Fracture Arm, Fracture Closed of Lower End of Forearm, Unspecified, Fracture Elbow, Fracture Fixation, Fracture Fixation, Internal, Fracture Forearm, Fracture Distal Radius
Interventions: Lidocaine Infusion, Standard of Care (SOC); Drug · Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 16 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 10
States / cities: Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more

Conditions: Gout
Interventions: D-0120; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

SCI-110 in the Treatment of Tourette Syndrome

A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

A 12-Week Study in Adult Subjects With Asthma

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

Rivastigmine For Methamphetamine Dependent Individuals

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers